- Home
- PRME vs PDT Comparison
PRME vs PDT Comparison
Compare PRME & PDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRME | PDT |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.1M | 660.6M |
| IPO Year | 2022 | 1994 |
Fundamental Metrics
Financial Performance| Metric | PRME | PDT |
|---|---|---|
| Price | $3.77 | $13.28 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $6.42 | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 117.3K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,632,000.00 | N/A |
| Revenue This Year | $15.20 | N/A |
| Revenue Next Year | $316.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 55.28 | N/A |
| 52 Week Low | $1.11 | $11.41 |
| 52 Week High | $6.94 | $13.65 |
Technical Indicators
Market Signals| Indicator | PRME | PDT |
|---|---|---|
| Relative Strength Index (RSI) | 47.69 | 48.72 |
| Support Level | $3.73 | $13.21 |
| Resistance Level | $4.66 | $13.47 |
| Average True Range (ATR) | 0.30 | 0.14 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 39.73 | 35.59 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About PDT John Hancock Premium Dividend Fund
John Hancock Premium Div Fund is a United States-based closed-end management investment company. It seeks to provide a high current income consistent with modest capital growth. The fund will pursue its objective by investing in a diversified portfolio comprised of dividend-paying preferred securities and common equity securities. The portfolio composition of the fund consists of preferred securities, common stocks, corporate bonds, capital preferred securities, and short-term investments.